RecruitingPhase 2

LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

Canada128 participantsStarted 2025-04-07

Plain-language summary

This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual immunotherapy treatment called Immune Checkpoint Blockade (ICB)? FMT treatment changes the bacteria in your gut called the microbiome.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. without evidence of progression for at least four weeks prior to randomization and have no evidence of new or enlarging brain metastases; or
✕. treated with surgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases; or
✕. treated with stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
✕. asymptomatic or minimally symptomatic active metastases, with controlled steriod use and no imminent CNS complications.

What they're measuring

Progression-free Survival

Timeframe: 4 years

Trial details

NCT IDNCT06623461

SponsorCanadian Cancer Trials Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2028-12-31

Contact for this trial

Janet Dancey

613-533-6430 jdancey@ctg.queensu.cca

View on ClinicalTrials.gov More Melanoma trials